Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 17/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 9/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6913440 | 0.95 | ADRB3 (0.66) | ADRB3ADRB2ADRB1LTA4HPLA2G2A | |
| SCHEMBL6911769 | 0.92 | ADRB3 (0.54) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6906589 | 0.90 | ADRB3 (0.52) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6914240 | 0.88 | ADRB3 (0.62) | ADRB3ADRB2ADRB1PTGS1SLC6A2 | |
| SCHEMBL6914248 | 0.85 | ADRB3 (0.53) | ADRB3ADRB2ADRB1PTGS1SLC6A2 | |
| SCHEMBL6914776 | 0.83 | ADRB3 (0.65) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7765020 | 0.83 | ADRB3 (0.55) | ADRB3ADRB2ADRB1PTGS1SLC6A2 | |
| SCHEMBL6912814 | 0.82 | ADRB3 (0.51) | ADRB3ADRB2ADRB1MEN1ALDH1A1 | |
| SCHEMBL6914778 | 0.81 | ADRB3 (0.51) | ADRB3ADRB2ADRB1MEN1ALDH1A1 | |
| SCHEMBL27612125 | 0.77 | ADRB3 (0.74) | ADRB3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242485-A1 | Compositions and methods for the amelioration of leptin resistance | KADOWAKI TAKASHI (JP) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242485-A1 | Compositions and methods for the amelioration of leptin resistance | ADIPOR1, FABP4, ADIPOR2 | ADRB3 6/4885ADRB2 17/4885ADRB1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.